Navigation Links
Uterine Cancer May be Clue to Inherited Syndrome

A new study suggests that women with endometrial cancer should be screened for inherited mutations that could lead to a high risk of several other cancers.//

The study showed that 1.8 percent, or about one in 50, of newly diagnosed endometrial cancer patients have mutations for Lynch syndrome, an inherited condition also known as hereditary nonpolyposis colon cancer, or HNPCC.

People with Lynch syndrome mutations are at high risk for colon, endometrial, ovarian and gastric cancer. Endometrial, or uterine, cancer is the most common cancer in women with this condition.

The study is the first to comprehensively screen a large number of women with uterine cancer for Lynch syndrome mutations, said Heather Hampel, a genetic counselor in the clinical cancer genetics program and first author of the study.

“It’s important to identify women with one of these mutations because they have a very high risk for developing colon cancer, and they may not be aware of that risk,” said Hampel. “Because this is hereditary, half of her siblings and children may also be at risk for the syndrome.

“For this reason, the relatives of a person with Lynch syndrome should also be screened for the responsible gene mutation,” said Hampel, a clinical assistant professor in the department of internal medicine.

Family members who also have the mutation need close monitoring for early cancer detection, including an annual colonoscopy starting at age 25 and endometrial cancer screening (using ultrasounds and biopsies) starting at age 30, Hampel said.

Family members without the mutation can follow the American Cancer Society’s guidelines for colorectal cancer screening, which call for a colonoscopy every 10 years starting at age 50 and no routine endometrial cancer screening, she said.

This study involving 543 women was led by Albert de la Chapelle, co-leader of the OSUCCC Molecular Biology and Cancer Genetic s Program. Participants in the study were diagnosed and treated for endometrial cancer at the three major hospital systems in Columbus, Ohio, between 1999 and 2003.

To learn the frequency of Lynch syndrome mutations among all newly diagnosed endometrial cancer patients, the researchers tested tissue from the tumors from each patient for MSI (microsatellite instability), a change in the DNA of tumor cells that occurs in more than 90 percent of Lynch syndrome tumors. Of the 543 tumors tested, 118 showed MSI. Because these patients are more likely to have Lynch syndrome, they participated in the gene testing portion of the study and nine (1.8 percent) were found to have Lynch syndrome mutations.

In addition, the researchers used another technique called immunohistochemistry, to prescreen the tumors for mutations. Follow-up gene testing performed on patients with abnormal immunohistochemistry results showed that one additional woman with an MSI-negative tumor also had a Lynch syndrome mutation.

Of the 10 Lynch syndrome patients, seven did not meet the usual criteria for diagnosing the hereditary condition. That diagnosis is largely based on family history and age. Ordinarily, these seven cases would have gone undiagnosed.

In addition, the counseling and testing of 21 relatives of the 10 women with Lynch syndrome revealed 10 additional people with Lynch syndrome mutations.

The study is the continuation of an Ohio State colon cancer study also led by de la Chapelle that was published in the New England Journal of Medicine in 2005. In that study, 2.2 percent of newly diagnosed colon cancer patients tested positive for Lynch syndrome.

That study recommended testing all newly diagnosed colon cancer patients for the inherited syndrome, Hampel said. As a result, Ohio State University Medical Center now routinely screens all newly diagnosed colon cancer patients to find those most likely to have Lynch syndr ome using the immunohistochemistry test, Hampel said. She hopes for a similar change in the standard of care for endometrial cancer patients as well.

“We think such genetic testing should be nationwide on all colon cancer and endometrial cancer patients, but further cost-benefit analysis and study is needed first,” Hampel said. “Screening for Lynch syndrome can save lives.”

(Source: ewswise)
'"/>




Related medicine news :

1. Uterine Fibroid Embolization Gaining Popularity
2. Embolization Effective For Uterine Fibroid
3. Outpatient Treatment Possible For Patients with Uterine Fibroid Tumors
4. Uterine Cancer Cases On The Rise
5. Brazilian Women to Be Vaccinated To Prevent Uterine Cancer
6. Uterine cancer may be associated with inherited mutations and a risk of many cancers
7. Uterine Cancer More Lethal For Black Women
8. Human Uterine Transplant In Near Future
9. Mifepristone Reliable For Treating Uterine Fibroids
10. Fibroids unlikely to Turn Cancerous
11. Virus Level could Predict Cervical Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... ... 30, 2017 , ... The Aresty Institute of Executive Education ... to address the increasingly complex educational needs of today's global executives. Corporate ... corporate finance and will increase their ability to confidently take action in ways ...
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... , ... March 30, 2017 , ... CHARM CITY RUN ... Run has announced that Mercy Medical Center will serve as the official title sponsor ... region. On Sunday, June 25, 2017, thousands of women will walk or run the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a proud ... the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, ... visionary leader in the training of physicians, scientists, and members of the public ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... , March 29, 2017 Today, CVS Health ... Kim Reynolds , Department of Public Health Director ... Steve Lukan in announcing the availability of the ... Pharmacy locations in Iowa.  CVS Health has established a standing ... allows CVS Pharmacy to expand access to the medication in ...
(Date:3/29/2017)... CREEK, Calif. , Mar 29, 2017 /PRNewswire/ ... cervical-fusion technology, announced the addition of two industry ... Lynch has joined the company to lead ... assuming International leadership.  Together, Mr. Lynch and Mr. ... experience.  Mr. Lynch joins the ...
Breaking Medicine Technology: